tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Andrew Tsai, 75 are a BUY (90.36%), 8 are a HOLD (9.64%).
Analyst Andrew Tsai, currently employed at JEFFERIES, carries an average stock price target met ratio of 55.2% that have a potential upside of 42.68% achieved within 164 days.
Andrew Tsai’s has documented 174 price targets and ratings displayed on 28 stocks. The coverage is on Healthcare, Technology sectors.
Most recent stock forecast was given on NERV, Minerva Neurosciences at 14-Aug-2026.
Analyst best performing recommendations are on VNDA (VANDA PHARMACEUTICALS).
The best stock recommendation documented was for SUPN (SUPERNUS PHARMACEUTICALS) at 6/15/2020. The price target of $24 was fulfilled within 1 day with a profit of $0.93 (4.03%) receiving and performance score of 40.31.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 07-Jul-2022
$5
$-2.66 (-34.73%)
$500
2 years 18 days ago
(19-Sep-2024)
2/4 (50%)
$0.35 (7.53%)
251
Buy Since 24-Mar-2023
2 years 1 months 3 days ago
(04-Sep-2024)
0/2 (0%)
$161.9 (576.16%)
Buy Since 10-May-2022
$100
2 years 1 months 3 days ago
(04-Sep-2024)
0/2 (0%)
$75.4 (306.50%)
Hold Since 29-May-2023
$50
3 years 4 months 8 days ago
(29-May-2023)
0/3 (0%)
$22.5 (81.82%)
Hold Since 23-Jun-2022
$30
$22.34 (291.64%)
$320
4 years 3 months 14 days ago
(23-Jun-2022)
2/7 (28.57%)
$2.5 (9.09%)
35
Which stock is Andrew Tsai most bullish on?
Which stock is Andrew Tsai most reserved on?
What Year was the first public recommendation made by Andrew Tsai?
